AI PRICE FORECAST
JNJ Stock Forecast & AI Price Prediction
Johnson & Johnson · Healthcare · Drug Manufacturers - General
JNJ live signal snapshot
JNJ last traded at $280.41, down 0.13% on the session, trading within 1.0% of its 52-week high of $283.25. Our AI model's current call on JNJ is BUY, with 86% confidence. Short-term momentum is constructive: the 5-, 10- and 20-day moving averages are stacked upward and price is holding above the 50-day average. The model's one-month path points toward roughly $290.78 (3.7% from here).
On the 14-day relative strength index, JNJ reads 68.0, showing buyers in control without the stretch of an overbought reading. Its MACD line is above its signal line with a positive histogram (1.51) — upward momentum is accelerating. The 50-day moving average ($266.55) sits 7.0% above the 200-day ($249.22) — a "golden cross" structure that typically supports the longer-term uptrend.
The average 12-month target from 22 Wall Street analysts is $279.41 (range $190.00–$320.00) — 0.4% downside from where JNJ trades now. The current recommendation trend leans bullish: 16 Buy/Strong Buy ratings vs 1 Sell/Strong Sell (and 6 Hold).
Live figures from real market data feeds, current as of the last site build. Open the interactive JNJ dashboard for numbers updated throughout today's session.
About Johnson & Johnson
Johnson & Johnson (JNJ) is a drug manufacturers - general company in the healthcare sector, headquartered in New Brunswick, NJ, United States. Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It has a market value of about $675.0 billion and roughly 138,200 full-time employees. With a beta of 0.2, the stock has historically moved less than the overall market.
JNJ performance vs. the market
Since the start of 2026 the stock has risen 35.5%, ahead of the S&P 500 (+11.4%) and ahead of the healthcare sector fund XLV (+22.1%). On a one-year view it is up 48.8%, 37.3 points better than the S&P 500. The last month (+12.8%) continues the three-month advance (+7.0%).
| Period | JNJ | Sector (XLV) | S&P 500 |
|---|---|---|---|
| 1 month | +12.8% | +11.4% | −2.3% |
| 3 months | +7.0% | +12.2% | −2.3% |
| Year to date | +35.5% | +22.1% | +11.4% |
| 1 year | +48.8% | +28.3% | +11.5% |
Johnson & Johnson financials at a glance
In the quarter ended Sep 30, 2026, Johnson & Johnson reported revenue of $25.4 billion and net income of $210 million (a 0.8% net margin). Revenue was up 5.9% from the same quarter a year earlier. The stock trades at a price-to-earnings ratio of 42.6 on trailing earnings of $6.59 per share. Trailing free cash flow was $18.5 billion, and total debt equals 55% of shareholders' equity.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Sep 30, 2026 | $25.4B | $210M |
| Jun 30, 2026 | $25.3B | $5.5B |
| Mar 31, 2026 | $24.1B | $5.2B |
| Dec 31, 2025 | $24.6B | $5.1B |
JNJ vs. its peers
Against 5 of its largest healthcare peers, JNJ's +35.5% year-to-date return beats 2 of them. The strongest of the group this year is Amgen (AMGN, +43.0%).
| Company | Price | YTD | P/E | AI verdict |
|---|---|---|---|---|
| Johnson & Johnson (JNJ) | $280.41 | +35.5% | 42.6 | BUY |
| Eli Lilly and (LLY) | $1,437.29 | +33.7% | 46.7 | BUY |
| AbbVie (ABBV) | $294.98 | +29.1% | 50.7 | BUY |
| Merck & Co. (MRK) | $147.18 | +39.8% | 148.7 | HOLD |
| Amgen (AMGN) | $468.11 | +43.0% | 27.1 | BUY |
| Gilead Sciences (GILD) | $169.73 | +38.3% | — | BUY |
JNJ stock: common questions
What is the JNJ stock price target?
22 Wall Street analysts put the average 12-month target at $279.41, in a range of $190.00–$320.00, versus a recent price of $280.41. Stock Pulse 247's model projects about $290.78 over the next month.
Is JNJ a buy right now?
Our AI model currently rates JNJ a BUY at 86% confidence. Among analysts, 16 rate it Buy or Strong Buy, 6 Hold and 1 Sell. Neither is personal advice — weigh them with your own research and risk tolerance.
How has JNJ stock performed this year?
Since the start of 2026 the stock has risen 35.5%, ahead of the S&P 500 (+11.4%) and ahead of the healthcare sector fund XLV (+22.1%). On a one-year view it is up 48.8%, 37.3 points better than the S&P 500. The last month (+12.8%) continues the three-month advance (+7.0%).
What is JNJ's 52-week high and low?
JNJ has traded between $193.07 and $283.25 over the past 52 weeks; at $280.41 it is within 1.0% of its 52-week high of $283.25.
What sector is JNJ in, and who are its peers?
JNJ is in the healthcare sector (drug manufacturers - general). Its largest peers on Stock Pulse 247 include Eli Lilly and (LLY), AbbVie (ABBV), Merck & Co. (MRK), Amgen (AMGN).
How accurate is the JNJ forecast?
It's a model estimate from price history, technical indicators and analyst targets, not a guarantee — no model predicts short-term moves reliably. Use it as one input alongside your own research.
How this works: the forecast combines JNJ's price history, momentum indicators (RSI, MACD, moving averages), volatility and analyst targets into one estimate. It's a model, not a guarantee.